Application of Nanopore Adaptive Sequencing

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorShenzhen Third People's Hospital

About this trial

Infection post liver transplantation is an important factor in the death in patients. The traditional method of diagnosing infection post liver transplantation is laboratory tests. But the sensitivity and specificity of blood tests is poor. Next-generation sequencing (NGS) has greater detection rate for mycobacterium tuberculosis, anaerobes and fungi and greater sensitivity compare with blood tests. However use of NGS is limited because of the short read-length. Oxford nanopore adaptive sequencing (NAS) method is the Third Revolution in Sequencing Technology. For each 1 Gbp of data, NAS sequencing detected 45 times more microbiome sequences than Nanopore standard sequencing and 2.5 times more than Illumina sequencing. The purpose of this study is to compare NAS with NGS and laboratory tests for the diagnostic rate of infection post liver transplantation.

Eligibility criteria

Qualifiers

Accept liver transplantation

Signing informed consent voluntarily

Possessing ability to comprehend material information

Participating this study voluntarily

Disqualifiers

Participated another study

Graft loss

Have undergone a multi-organ transplantion or have had a previous organ transplantation

Patient died

Trial design

Treatments tested in this trial

  • NAS, NGS and Laboratory tests

Treatment groups

100 Participants
are divided into 3 treatment groups